Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Net (2021 - 2025)

Historic Receivables - Net for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $345.5 million.

  • Apellis Pharmaceuticals' Receivables - Net rose 2384.39% to $345.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.5 million, marking a year-over-year increase of 2384.39%. This contributed to the annual value of $264.9 million for FY2024, which is 2832.95% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Receivables - Net stood at $345.5 million for Q3 2025, which was up 2384.39% from $214.1 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Receivables - Net registered a high of $345.5 million during Q3 2025, and its lowest value of $719000.0 during Q2 2021.
  • Moreover, its 5-year median value for Receivables - Net was $140.1 million (2023), whereas its average is $137.4 million.
  • In the last 5 years, Apellis Pharmaceuticals' Receivables - Net surged by 257169.66% in 2023 and then tumbled by 2966.24% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Receivables - Net (Quarter) stood at $10.1 million in 2021, then dropped by 23.52% to $7.7 million in 2022, then soared by 2571.7% to $206.4 million in 2023, then increased by 28.33% to $264.9 million in 2024, then soared by 30.43% to $345.5 million in 2025.
  • Its last three reported values are $345.5 million in Q3 2025, $214.1 million for Q2 2025, and $235.2 million during Q1 2025.